X
<

Who's Thanking Align Technology This November?

PART:
1 2 3 4 5
Part 5
Who's Thanking Align Technology This November? PART 5 OF 5

What’s Driving Invisalign Demand for Align in North America?

Teens

In 3Q17, Align Technology (ALGN) reported the use of Invisalign clear aligners by ~698,000 teens, which represents YoY (year-over-year) growth of ~46.5% and sequential growth of ~26.5%. The majority of teen demand in North America, which arises from the orthodontic channel, witnessed YoY growth of ~43.6% and sequential growth of ~22.9% in 3Q17.

This performance highlighted Align’s success in its sales initiatives as well as its targeted promotional campaigns designed for teens and moms. In 3Q17, Align witnessed 65.7% YoY growth and 36.7% sequential growth in teen cases in international markets, specifically driven by increased uptake in China.

What&#8217;s Driving Invisalign Demand for Align in North America?

Interested in ALGN? Don't miss the next report.

Receive e-mail alerts for new research on ALGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Invisalign cases by teens have risen rapidly since 1Q16. Rapid adoption by the teen segment is evolving as a major differentiating factor for Align, compared with other dental equipment providers like Danaher (DHR), Dentsply Sirona (XRAY), and 3M Company (MMM).

Notably, Align Technology accounts for 0.06% of the iShares Russell 1000 Growth ETF’s (IWF) total portfolio holdings.

Invisalign treatment with mandibular advancement

The launch of Invisalign treatment with mandibular advancement is expected to target a significant share of the teen segment requiring class-II corrections. This product could play a major role in increasing the adoption of Invisalign by teens, as 30%–45% of these patients require class-II corrections. But the product is awaiting approval from the FDA (US Food and Drug Administration).

X

Please select a profession that best describes you: